natgillin/translations-raw huggingface dataset:
Allergic reactions: If you experience allergic reactions such as chest tightness, wheezing, dizziness or rash, do not inject more Benepali, and contact your doctor immediately.
Alergijske reakcije: Če se pojavi alergijska reakcija, npr. tiščanje v prsnem košu, piskajoče dihanje, omotica ali izpuščaj, prenehajte injicirati zdravilo Benepali in nemudoma obvestite zdravnika.
Allergic reactions: If you or the child experience allergic reactions such as chest tightness, wheezing, dizziness or rash, do not inject more Enbrel, and contact your doctor immediately.
Alergijske reakcije: Če se pri vas ali otroku pojavijo alergijske reakcije, na primer tiščanje v prsnem košu, piskajoče dihanje, omotica ali izpuščaj, prenehajte injicirati zdravilo Enbrel in nemudoma obvestite zdravnika.
Allergic reactions: you may notice your breathing suddenly gets worse immediately after using Aerivio Spiromax.
Alergijske reakcije: opazite lahko, da se dihanje poslabša takoj po uporabo zdravila Airexar Spiromax.
Allergic reactions; fever; itching; antibodies directed against normal tissue (autoantibody formation).
Alergijske reakcije; vročina; srbenje; protitelesa proti normalnemu tkivu (nastanek avtoprotiteles).
Allergic reactionsam
alergijske reakcijeam
Allergic respiratory symptom.
alergijski simptomi v dihalih
allergic rhinitis (see section 5.1) urticaria (see section 5.1)
alergijskega rinitisa (glejte poglavje 5.1) urtikarije (glejte poglavje 5.1)
allergic rhinitis (see section 5.1) urticaria (see section 5.1)
alergijskega rinitisa (glejte poglavje 5.1), urtikarije (glejte poglavje 5.1).
allergic rhinitis (see section 5.1), urticaria (see section 5.1).
alergijskega rinitisa (glejte poglavje 5.1), urtikarije (glejte poglavje 5.1).
Allergic Skin Reactions (including rash) Pruritus
Alergijske kožne reakcije (vključno z izpuščajem)
allergic skin reactions such as redness, irritation, itching
alergijske kožne reakcije, kot so rdečina, draženje, srbenje
allergic to alemtuzumab or any of the other ingredients of this medicine (listed in section 6) infected with human immunodeficiency virus (HIV).
alergični na alemtuzumab ali katero koli sestavino tega zdravila (navedeno v poglavju 6); okuženi z virusom človeške imunske pomanjkljivosti (HIV).
Allergic type hypersensitivity reactions are possible with ALPROLIX.
Z zdravilom ALPROLIX so možne preobčutljivostne reakcije alergijskega tipa.
Allergic type hypersensitivity reactions are possible with Iblias.
Ofnæmi er hugsanlegt við notkun Iblias.
Allergic type reactions have been manifested by dyspnea, pruritus, generalised urticaria and rash.
Alergijske reakcije so se pokazale z dispnejo, srbenjem, generalizirano urtikarijo in izpuščajem.
Allergic type symptoms (e.g. anaphylactoid reaction or -shock, face oedema, urticaria)
imptomi alergijske vrste (npr. anafilaktoidna reakcija ali šok, otekanje obraza, koprivnica)
allergic vasculitis
alergijski vaskulitis
Allergic, hypersensitivity or anaphylactic reactions.
Alergijske, preobčutljivostne ali anafilaktične reakcije.
Allergic- type reactions including facial swelling, swollen tongue and pharyngeal oedema1
alergijske reakcije, vključno z oteklostjo obraza, oteklostjo jezika in faringealnim edemom1
allergic-type reactions such as bronchospasm (excessive and prolonged contraction of the airway muscles), cold-like symptoms, polyps in the nose, swelling of the face or hives after taking aspirin or NSAIDs, including other COX-2 inhibitors;
alergijskimi reakcijami, kot so bronhospazem (prekomerno in dlje časa trajajoče skrčenje mišic v dihalnih poteh), prehladu podobni simptomi, polipi v nosu, otekanje obraza ali izpuščaji po zaužitju aspirina ali nesteroidnih protivnetnih zdravil, vključno z drugimi zaviralci COX-2;
allergic-type reactions, including redness and flushing, skin rash, and raised areas of the skin that itch.
reakcije alergijske vrste, vključno s pordelostjo in zardevanjem, izpuščajem na koži in dvignjenimi predeli kože, ki srbijo.
allergies
alergija
allergies (including seasonal allergy)
alergije (vključno s sezonsko alergijo)
allergy
alergija,
allergy
alergijo,
Allergy aggravated
poslabšanje alergije
Allergy is very rare (may affect up to 1 in 10,000 patients).
Alergija se pojavlja zelo redko (lahko se pojavi pri največ 1 od 10.000 bolnikov).
Allergy medicines such as fexofenadine and ranolazine
Zdravila proti alergijam, kot so feksofenadin in ranolazin
Allergy medicines such as fexofenadine and ranolazine
Zdravila proti alergijam, kot sta feksofenadin in ranolazin
allergy to the medicine
alergija na zdravilo,
allergy, dehydration, headache, skin rash, itching
alergija, dehidracija, glavobol, kožni izpuščaj, srbečica,
Allergy-like reaction Impairment of taste Dizziness
reakcije, podobne alergijam motnje okusa
Allergy: generalized allergic reactions including swelling beneath the skin that can occur in areas such as the face and limbs, and can obstruct the airway which may cause difficulty swallowing or breathing, localized and generalized rash, itchiness, severe sudden life-threatening allergic reaction.
Alergije: razširjene alergijske reakcije, ki vključujejo otekline pod kožo na področjih obraza in udov in ki lahko ovirajo dihalne poti, to pa lahko povzroči težave pri požiranju ali dihanju, koprivnica, omejen ali razširjen izpuščaj, srbenje, huda nenadna življenjsko nevarna alergijska reakcija
Allergy: increased allergic symptoms, generalised allergic reactions including swelling beneath the skin that can occur in areas such as the face and limbs and can obstruct the airway which may cause difficulty swallowing or breathing, hives, localised and generalised rash, itchiness, severe sudden life-threatening allergic reaction.
Alergije: močnejši alergijski simptomi, razširjene alergijske reakcije, ki vključujejo otekline pod kožo na področjih obraza in udov in ki lahko ovirajo dihalne poti, to pa lahko povzroči težave pri požiranju ali dihanju, koprivnica, omejen ali razširjen izpuščaj, srbenje, huda nenadna življenjsko nevarna alergijska reakcija.
Alleviates inflammation and pain in acute and chronic musculo-skeletal disorders in cats.
Umirjanje vnetja in lajšanje bolečine pri akutnih in kroničnih mišično-skeletnih obolenjih pri mačkah.
Alleviation of acute anxiety and fear associated with noise in dogs.
Lajšanje akutne, s hrupom povezane tesnobe in strahu pri psih.
Alleviation of inflammation and pain in acute and chronic musculo-skeletal disorders.
Umirjanje vnetja in lajšanje bolečine pri akutnih in kroničnih mišično-skeletnih obolenjih pri mačkah.
Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders in dogs.
Umirjanje vnetja in lajšanje bolečine pri akutnih in kroničnih mišično – skeletnih obolenjih pri psih.
Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders in dogs.
Umirjanje vnetja in lajšanje bolečine pri akutnih in kroničnih mišično-skeletnih obolenjih.
Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders in horses.
Umirjanje vnetja in lajšanje bolečine pri akutnih in kroničnih mišično-skeletnih obolenjih pri konjih.
Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders in horses.
Umirjanje vnetja in lajšanje bolečine pri akutnih in kroničnih mišično-skeletnih obolenjih.
Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders.
Umirjanje vnetja in lajšanje bolečine pri akutnih in kroničnih mišično – skeletnih obolenjih.
Alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders in horses weighing between 500 and 600 kg.
Umirjanje vnetja in lajšanje bolečine pri akutnih in kroničnih mišično-skeletnih obolenjih pri konjih ki tehtajo med 500 in 600 kg.
Alleviation of inflammatory and clinical parameters associated with recurrent airway obstruction (RAO) in horses, in combination with environmental control.
Lajšanje vnetnih in kliničnih znakov, povezanih s ponavljajočo se obstrukcijo dihal (recurrent airway obstruction – RAO) pri konjih, v kombinaciji z okoljskimi ukrepi.
Alleviation of pain and inflammation associated with osteoarthritis and reduction of associated lameness in horses
Lajšanje bolečine in vnetja, povezanih z osteoartritisom in zmanjšanje šepanja, povezanega z osteoartritisom pri konjih.
Alleviation of pain and inflammation associated with osteoarthritis and reduction of associated lameness in horses.
Lajšanje bolečine in vnetja s pridruženim osteoartritisom in za zmanjšanje sočasnega šepanja pri konjih.
Alleviation of pain and inflammation associated with osteoarthritis and reduction of associated lameness in horses.
Lajšanje bolečine in vnetja, povezanih z osteoartritisom in zmanjšanje šepanja, povezanega z osteoartritisom pri konjih.
Alleviation of pain and inflammation in chronic musculo-skeletal disorders in cats.
Lajšanje bolečine in umirjanje vnetja pri kroničnih mišično – skeletnih obolenjih pri mačkah.
alli 27 mg chewable tablets
alli 27 mg žvečljive tablete
alli 27 mg chewable tablets Orlistat
alli 27 mg žvečljive tablete orlistat
alli 27 mg chewable tablets:
alli 27 mg žvečljive tablete:
alli 60 mg hard capsules
alli 60 mg trde kapsule
alli 60 mg hard capsules
alli 60 mg trde kapsule orlistat
alli 60 mg hard capsules Orlistat
alli 60 mg trde kapsule orlistat
alli 60 mg hard capsules: Medicinal product not subject to medical prescription. alli 27 mg chewable tablets: Medicinal product not subject to medical prescription.
alli 60 mg trde kapsule: Izdaja zdravila je brez recepta v lekarnah. alli 27 mg žvečljive tablete: Izdaja zdravila je brez recepta v lekarnah.
alli can be taken immediately before, during a meal or up to one hour after a meal.
Zdravilo alli lahko vzamete tik pred obroki, med njimi ali največ eno uro po njih.
alli capsules have a turquoise cap and body, with a dark blue band round the middle, imprinted with "alli".
Kapsule alli imajo ovoj in pokrovček turkizne barve, na sredi pa temno modro črto in napis »alli«.
alli contains lactose and sucrose
Zdravilo alli vsebuje laktozo in saharozo.
alli is indicated for weight loss in adults who are overweight (body mass index, BMI, 28 kg/m2) and should be taken in conjunction with a mildly hypocaloric, lower-fat diet.
Zdravilo alli je indicirano za zmanjševanje telesne mase pri odraslih s čezmerno telesno maso (indeks telesne mase ITM  28 kg/m2), ob hkratni nizkokalorični dieti z zmanjšanim vnosom maščob.
alli is unlikely to affect your ability to drive and use machines.
Malo je verjetno, da bi jemanje zdravila alli vplivalo na sposobnost vožnje ali upravljanja s stroji.
alli may affect some medicines you have to take.
Nekatera zdravila lahko vplivajo na delovanje zdravila alli ali pa zdravilo alli lahko vpliva na njihovo delovanje.
alli should be used along with a reduced calorie, lower-fat diet.
Zdravilo alli je treba jemati skupaj z dieto z zmanjšanim vnosom kalorij in maščob.
alli should be used along with a reduced calorie, lower-fat diet.
Zdravilo alli jemljite skupaj z uravnoteženo nizkokalorično dieto z malo maščobami.
alli should not be taken for more than six months.
Zdravila alli ne smete jemati več kot 6 mesecev.
alli with food and drink
Zdravilo alli skupaj s hrano in pijačo
ALLIANCE MEDICAL MOLECULAR IMAGING LTD. - GUILDFORD
ALLIANCE MEDICAL MOLECULAR IMAGING LTD.
Alliance Medical Molecular Imaging Ltd., UK
Alliance Medical Molecular Imaging Ltd., VB
ALLOGENEIC HPCT
ALOGENSKA PKMC
Allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (ΔLNGFR) and the herpes simplex I virus thymidine kinase (HSV-TK Mut2)
Alogenske celice T, gensko spremenjene z retrovirusnim vektorjem, kodirane za skrajšano obliko humanega receptorja živčnega rastnega faktorja z nizko afiniteto (ΔLNGFR-low affinity nerve growth factor receptor) in timidin-kinazo virusa herpesa simpleksa I (HSV-TK Mut2)
Allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (ΔLNGFR) and the herpes simplex I virus thymidine kinase (HSV-TK Mut2)
Alogenske celice T, gensko spremenjene z retrovirusnim vektorjem, kodirane za skrajšano obliko človeškega receptorja živčnega rastnega faktorja z nizko afiniteto (ΔLNGFR-low affinity nerve growth factor receptor) in timidin-kinazo virusa herpesa simpleksa I (HSV-TK Mut2).
Allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (ΔLNGFR) and the herpes simplex I virus thymidine kinase (HSV-TK Mut2).
Alogenske celice T, gensko spremenjene z retrovirusnim vektorjem, kodirane za skrajšano obliko humanega receptorja živčnega rastnega faktorja z nizko afiniteto (ΔLNGFR-low affinity nerve growth factor receptor) in timidin-kinazo virusa herpesa simpleksa I (HSV-TK Mut2).
Allopurinol and other xanthine oxidase inhibitors decrease the rate of catabolism of
Alopurinol in drugi zaviralci ksantin-oksidaze zmanjšujejo hitrost razgradnje 6-merkaptopurina.
allopurinol or febuxostat (used to treat gout)
alopurinol ali febuksostat (uporablja se za zdravljenje protina);
allopurinol, probenecid, sulfinpyrazone (to treat gout)
alopurinol, probenecid, sulfinpirazon (za zdravljenje protina)
Allow 10-15 minutes for the vial to warm to room temperature (15C - 25C).
Vialo pustite 10-15 minut, da se ogreje na sobno temperaturo (15 C–25 C).
Allow 10-15 minutes for the vial to warm to room temperature (15C - 25C).
Vialo pustite 10-15 minut, da se ogreje na sobno temperaturo (15–25C).
Allow refrigerated product to come to room temperature before use.
Ohlajeno zdravilo pred uporabo segrejte na sobno temperaturo.
Allow the alcohol to dry on the skin before fixing the administration system into place.
Preden pritrdite aplikacijski sistem, počakajte, da se alkohol na koži posuši.
Allow the application site to dry before permitting contact with such materials.
Pred stikom zdravila s takšnimi površinami, naj se mesto nanosa posuši.
Allow the application site to dry before permitting contact with such materials.
Preden dovolite stik izdelka s takšnimi površinami, naj se mesto nanosa posuši.
Allow the area to dry for 15 minutes.
Počakajte 15 minut, da se posuši.
Allow the bird to blink before releasing it.
Počakajte, da ptica mežikne, preden jo spustite.
Allow the gel to dry for three to five minutes before covering a treated area with loose clothing.
Pustite gel sušiti tri do pet minut, preden zdravljene predele kože pokrijete z ohlapnim oblačilom.
Allow the injection area to dry.
Pustite, da se koža na mestu injiciranja posuši.
Allow the lyophilisate to dissolve completely.
Počakajte, da se liofilizat povsem razpusti.
Allow the pen to sit at room temperature outside the box for 30 minutes before use.
Pred uporabo iglo pustite na sobni temperaturi 30 minut.
Allow the pen to sit at room temperature outside the box for 30 minutes before use.
Pred uporabo pero 30 minut pustite na sobni temperaturi izven škatle.
Allow the pen to sit at room temperature outside the box for 30 minutes before use.
Pred uporabo pero pustite na sobni temperaturi 30 minut izven škatle.
Allow the pre- filled pen to reach room temperature before injecting.
Pred injiciranjem morate napolnjen injekcijski peresnik pustiti, da doseže sobno temperaturo.
Allow the pre- filled syringe to reach room temperature before injecting.
Pred injiciranjem morate napolnjeno injekcijsko brizgo pustiti, da doseže sobno temperaturo.
Allow the pre-filled pen to adjust to room temperature
Pustite, da se napolnjeni injekcijski peresnik ogreje na sobno temperaturo
Allow the pre-filled syringe to reach room temperature.
Pred injiciranjem naj se napolnjena injekcijska brizga segreje na sobno temperaturo.
Allow the reconstituted vaccine to sit for 1 minute and then carefully swirl the contents to mix.
Rekonstituirano cepivo naj stoji 1 minuto, nato vsebino previdno obračajte, da se zmeša.
Allow the required number of Docefrez boxes which are stored in a refrigerator, to stand at room temperature (below 25ºC) for 5 minutes.
Če so viale shranjene v hladilniku, pustite potrebno število škatel Docefrez 5 minut stati na sobni temperaturi (do 25 °C).
Allow the solution to reach room temperature before injection or warm the syringe between your palms.
Pred injiciranjem naj ima raztopina sobno temperaturo, brizgo lahko ogrejete tudi med dlanmi.
Allow the solvent to flow into the powder vial.
Počakajte, da vehikel steče v vialo s praškom.
Allow the solvent to reach room temperature (15 - 25C).
Vehikel se mora ogreti na sobno temperaturo (15 do 25 ºC).
Allow the solvent to reach room temperature.
Počakajte, da se vehikel ogreje na sobno temperaturo (15 do 25 ºC).
Allow the sterile solvent to reach room temperature (15–25 C).
Počakajte, da se sterilni vehikel ogreje na sobno temperaturo (15–25 °C).
Allow the syringe to air-dry and store with the bottle. syringe.
Brizgo pustite, da se posuši, nato pa jo shranite skupaj s steklenico.
Allow the syringe to sit at room temperature outside the box for 25 to 30 minutes before use
Vzemite brizgo iz škatle in jo pustite na sobni temperaturi 25 do 30 minut pred uporabo
Allow the syringe to sit at room temperature outside the box for 30 minutes before use.
Pred uporabo iglo 30 minut pustite na sobni temperaturi izven škatle.
Allow the syringe to sit at room temperature outside the box for 30 minutes before use.
Pred uporabo iglo pustite na sobni temperaturi 30 minut.
Allow the vaccine to reach a temperature of 15 °C – 25 °C. Shake well before use.
Cepivo naj doseže temperaturo 15 °C – 25 °C. Pred uporabo ga dobro pretresite.
Allow the vaccine to reach a temperature of 15 C to 25 C before administration.
Cepivo se mora pred uporabo segreti na temperaturo med 15 C in 25C.
Allow the vaccine to reach a temperature of 15 C to 25 C before administration.
Cepivo se mora pred uporabo segreti na temperaturo med 15C in 25C.
Allow the vaccine to reach a temperature of 15°C - 25°C and shake well before use.
Cepivo ogrejte na 15 °C – 25 °C in ga pred uporabo dobro pretresite.
Allow the vaccine to reach a temperature of 15°C-25°C and shake well before use.
Cepivo ogrejte na 15 °C–25 °C in ga pred uporabo dobro pretresite.
Allow the vaccine to reach a temperature of 15°C-25°C. Use sterile syringes and needles
Cepivo pred uporabo ogrejemo na sobno temrperaturo 15 °C-25 °C. Uporabite sterilne brizge in igle.
Allow the vaccine to reach room temperature (15-25°C) before using the vaccine.
Cepivo pred uporabo ogrejte na sobno temperaturo (15-25 °C).
Allow the vaccine to reach room temperature (15-25˚C) before administration.
Pred uporabo počakajte, da se cepivo ogreje na sobno temperaturo (15-25 ˚C).
Allow the vaccine to reach room temperature (15-25˚C) before administration.
Pred uporabo počakajte, da se cepivo ogreje na sobno temperaturo (15-25˚C).
Allow the vaccine to reach room temperature (15–25 ºC) before administration.
Pred uporabo počakajte, da se cepivo ogreje na sobno temperaturo (15–25 °C).
Allow the vial kit to warm to 15 C - 30 C and place it in a suitable shielding container and sanitise the rubber septum with sanitising alcohol swab.
Pustite komplet z vialo, da se segreje na 15˚C-30˚C in ga namestite v primeren zaščitni vsebnik in očistite gumijasto pregrado s čistilno alkoholno blazinico.
Allow the vial to reach room temperature and inspect the liquid phase for particulate matter or precipitates before resuspension.
Počakajte, da viala doseže sobno temperaturo in pred resuspendiranjem preglejte tekočo fazo na vsebnost delcev ali oborin.
Allow the vial to reach room temperature before injecting.
Pred injiciranjem morate vialo pustiti, da doseže sobno temperaturo.
Allow the vial to sit at room temperature (15C - 25C) during reconstitution, gently swirling the vial for 60 seconds every 5 minutes until the powder is dissolved.
Med pripravo vialo pustite na sobni temperaturi (15–25 C) in jo vsakih 5 minut za 60 sekund nežno vrtite, dokler se prašek ne raztopi.
Allow the vial to sit at room temperature (15C - 25C) during reconstitution, gently swirling the vial for 60 seconds every 5 minutes until the powder is dissolved.
Med pripravo vialo pustite na sobni temperaturi (15C–25 C) in jo vsakih 5 minut za 60 sekund nežno vrtite, dokler se prašek ne raztopi.
Allow the vials to dry before opening the Mix2Vial (device pack), then follow the instructions given below.
Pustite, da se viali posušita, preden odprete zavoj Mix2Vial (škatla s pripomočkom), nato sledite spodnjim navodilom.
Allow the vials to dry before opening the Mix2Vial package (which contains the filter transfer device), then follow the instructions given below.
Pustite, da se viali posušita, preden odprete zavoj Mix2Vial (ki vsebuje pripravo s filtrom za prenos), nato sledite spodnjim navodilom.
Allow to reach room temperature.
Pred injiciranjem naj se napolnjeni injekcijski peresnik segreje na sobno temperaturo.
Allow to stand for about 15 minutes at room temperature.
Vialo spet pustite, da stoji približno 15 minut pri sobni temperaturi.
Allow vaccine to reach room temperature (15-25°C) before using the vaccine.
Cepivo pred uporabo ogrejemo na sobno temperaturo (15-25 °C).
Allow vials to reach room temperature.
Počakajte, da se ogreje na sobno temperaturo.
Allow your pen to warm at room temperature before using.
Pred uporabo pustite, da se peresnik ogreje na sobno temperaturo.
Allow yourself enough time to inject the whole of the solution until the syringe is empty.
Vzemite si dovolj časa za injiciranje vse tekočine, dokler injekcijske brizge ne izpraznite.
Allowed background therapy included bosentan (stable maintenance dose up to 125 mg twice daily) and chronic anticoagulation, digoxin, diuretics and oxygen.
Dovoljena osnovna terapija je vključevala bosentan (stabilen vzdrževalni odmerek do 125 mg dvakrat dnevno), kronične antikoagulantno zdravljenje, digoksin, diuretike in kisik.
allows continued monitoring of the benefit/risk balance of the medicinal product.
Omogoča namreč stalno spremljanje razmerja med koristmi in tveganji zdravila.
Allée de la Recherche 60 (address only for outer carton)
Allée de la Recherche 60 (naslov samo za škatlo)
Allée de la Recherche 60 1070 Brussels
Allée de la Recherche 60 1070 Bruselj
Allée de la Recherche 60 B-1070 Brussels BELGIUM
Allee de la Recherche 60 B-1070 Brussels BELGIJA
Allée de la Recherche 60 B-1070 Brussels BELGIUM
Allée de la Recherche 60 B-1070 Bruxelles BELGIJA
Allée de la Recherche 60 B-1070 Bruxelles
Allée de la Recherche 60 B-1070 Bruxelles Belgija
Almac Pharma Services Limited, 20 Seagoe Industrial Estate, Craigavon, Co Armagh, BT63 5QD, United Kingdom.
Almac Pharma Services Limited, 20 Seagoe Industrial Estate, Craigavon, Co Armagh, BT63 5QD, Velika Britanija.
almeterol (used to treat asthma)
almeterol (uporabljamo ga za zdravljenje astme).
almeterol (used to treat asthma)
almeterol (zdravilo za zdravljenje astme),
almeterol is not recommended (see section 4.5); rivaroxaban is not recommended (see section 4.5).
almeterolom ni priporočljiva (glejte poglavje 4.5); rivaroksabanom ni priporočljiva (glejte poglavje 4.5).
almeterol is not recommended (see section 4.5); rivaroxaban is not recommended (see section 4.5).
almeterolom ni priporočljiva (glejte poglavje 4.5); rivaroksabanom ni priporočljiva.
almeterol, a medicine used to treat asthma
almeterol; zdravilo, ki se uporablja za zdravljenje astme
almonid fish
plemenke salmonidnih vrst rib
Almost 3,000 of the patients in the studies had essential thrombocythaemia, defined as a platelet count of more than 600 million/ml.
Skoraj 3 000 bolnikov v študijah je imelo esencialno trombocitemijo, ki je bila opredeljena kot število krvnih ploščic, večje od
Almost 4,000 patients from these 5 studies went on to enter studies looking at the long-term effects of RoActemra treatment and results showed that response to RoActemra is maintained for at least two years.
Skoraj 4 000 bolnikov iz teh petih študij je nato sodelovalo v študijah, ki so proučevale dolgoročne učinke zdravljenja z zdravilom RoActemra in rezultati so dokazali, da se bolniki na zdravilo RoActemra odzivajo vsaj dve leti.